Overactive Bladder Program
Overactive Bladder (OAB)
Pre-clinical/ClinicalActive
Key Facts
About Evestra
Evestra is a clinical-stage biotech specializing in women's health and oncology, built on two core technology platforms: innovative steroid medicinal chemistry and vaginal ring drug delivery. The company is advancing a pipeline addressing significant unmet needs in contraception, gynecological disorders, and oncology, with key assets likely in early to mid-stage development. Strategic initiatives include a partnership with the Bill & Melinda Gates Foundation for a long-acting contraceptive and an affiliated oncology startup in Poland, Evestra Onkologia, supported by European grants.
View full company profileTherapeutic Areas
Other Overactive Bladder (OAB) Drugs
| Drug | Company | Phase |
|---|---|---|
| KRP-118 | KYORIN Pharmaceutical | Phase 2 |
| Fesoterodine (Toviaz) | KYORIN Pharmaceutical | Approved |
| NiNA | EBT Medical | Pre-clinical |
| Weekly Microneedle Patch for Overactive Bladder | TSRL Inc | Pre-clinical |